Table III.
Cardiac resonance assessments
| Outcome | Placebo (n = 25) | Ascorbate (n = 15) | P-value |
|---|---|---|---|
| Infarct size (%): | |||
| 7–15 days | 21.5 (17.0–34.2) | 17.0 (13.0–36.0) | 0.6646 |
| 2–3 months | 19.0 (14.0–34.0) | 21.0 (14.0–34.0) | 0.9642 |
| LVEF (%): | |||
| 7–15 days | 49.1 (41.0–59.4) | 47.3 (40.0–56.4) | 0.5403 |
| 2–3 months | 47.5 (38.0–61.7) | 54.6 (39.9–64.8) | 0.4155 |
| IESV [ml/m2]: | |||
| 7–15 days | 45.0 (28.2–53.4) | 46.9 (25.0–54.5) | 0.8461 |
| 2–3 months | 47.0 (34.0–56.5) | 39.0 (25.0–60.8) | 0.3890 |
Values are expressed as median (interquartile range). LVEF – left ventricular ejection fraction, IESV – indexed end systolic volume.